Chronic dysimmune neuropathy. A subclassification based upon the clinical features of 102 patients
- PMID: 12796835
- DOI: 10.1007/s00415-003-1068-2
Chronic dysimmune neuropathy. A subclassification based upon the clinical features of 102 patients
Abstract
The Chronic Dysimmune neuropathies (CDN) are a clinically heterogeneous group of polyneuropathies united by their presumed immune mediated aetiology. At present such neuropathies are classified as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN) and the Neuropathies in association with serum Paraproteins (Paraproteinaemic Neuropathies). This classification fails to recognise other distinctive syndromes and is limited by heterogeneity within, and overlap between, subgroups. We have refined this clinical subclassification by a review of a consecutive series of 102 unselected patients with CDN referred to a single neurologist. We recognise 6 clinical subtypes of CDN: one sensory ataxic group; three motor-sensory subgroups (chronic motor sensory demyelinating neuropathy, subacute motor sensory demyelinating neuropathy and a multifocal motor sensory neuropathy); and two pure motor subgroups (symmetric pure motor demyelinating neuropathy and multifocal motor neuropathy). This subclassification allows distinct syndromes to be recognised and helps resolve problems of heterogeneity and overlap. Distinction between these subgroups is of immediate practical relevance to patient management. Although steroids are beneficial for most of the subgroups, this is not so for both of the pure motor syndromes which should be treated with intravenous immunoglobulin. Patients with chronic development of Motor Sensory Demyelinating Neuropathy respond less well to steroids than those with a subacute onset. An association was found between elderly patients with Subacute Motor Sensory Demyelinating Neuropathy and carcinomas. Within any clinical subgroup patients behave similarly regardless of the presence of associated paraproteins or nerve specific antibodies.
Similar articles
-
Treatment of immune-mediated, dysimmune neuropathies.Acta Neurol Scand. 2005 Aug;112(2):115-25. doi: 10.1111/j.1600-0404.2005.00448.x. Acta Neurol Scand. 2005. PMID: 16008538 Review.
-
Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy.J Neurol Sci. 2010 May 15;292(1-2):63-71. doi: 10.1016/j.jns.2010.02.002. Epub 2010 Mar 10. J Neurol Sci. 2010. PMID: 20219211
-
Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome.Brain. 2004 Sep;127(Pt 9):2010-7. doi: 10.1093/brain/awh222. Epub 2004 Aug 2. Brain. 2004. PMID: 15289267
-
The spectrum of acquired demyelinating polyradiculoneuropathy.Acta Neurol Belg. 1994;94(2):128-32. Acta Neurol Belg. 1994. PMID: 8036880 Review.
-
Motor and sensory demyelinating mononeuropathy multiplex (multifocal motor and sensory demyelinating neuropathy): a separate entity or a variant of chronic inflammatory demyelinating polyneuropathy?J Peripher Nerv Syst. 1997;2(4):362-9. J Peripher Nerv Syst. 1997. PMID: 10975745 Clinical Trial.
Cited by
-
Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern.BMC Neurol. 2014 Apr 4;14:72. doi: 10.1186/1471-2377-14-72. BMC Neurol. 2014. PMID: 24708554 Free PMC article. Clinical Trial.
-
Epidemiology of neuroimmunological diseases.J Neurol. 2006 Sep;253 Suppl 5:V2-8. doi: 10.1007/s00415-006-5001-3. J Neurol. 2006. PMID: 16998750 Review.
-
Movement disorders and neuropathies: overlaps and mimics in clinical practice.J Neurol. 2022 Sep;269(9):4646-4662. doi: 10.1007/s00415-022-11200-0. Epub 2022 Jun 3. J Neurol. 2022. PMID: 35657406 Review.
-
Motor-dominant chronic inflammatory demyelinating polyneuropathy.J Neurol. 2010 Apr;257(4):621-9. doi: 10.1007/s00415-009-5386-x. Epub 2009 Nov 22. J Neurol. 2010. PMID: 20361294 Clinical Trial.
-
Deterioration in multifocal motor neuropathy upon treatment of immune-related adverse events of checkpoint inhibition.Immunotherapy. 2024;16(9):597-601. doi: 10.1080/1750743X.2024.2342238. Epub 2024 May 16. Immunotherapy. 2024. PMID: 39052281 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources